Erin Grady, MD, CCD, FACNM, FSNMMI is a nuclear medicine physician at Stanford Hospital and Clinics in Stanford, California. She is actively involved nationally in the SNMMI in multiple capacities including as a Director-at-Large on the SNMMI Board of Directors, chair of the Nuclear Medicine Program Directors, a member of the General Nuclear Medicine Council board, co-chair of the Government Relations Committee and a longstanding member of the Coding and Reimbursement Committee. In addition, she is a past chair of the American Board of Nuclear Medicine and has served on the board of appeals panel, review committee and milestone development committee for Nuclear Medicine and milestone revision committee for Nuclear Radiology at the ACGME. Her areas of research interest include quality, education, radiopharmaceutical therapy and finding answers to clinical questions that arise during the course of practice. She is passionate about education in nuclear medicine, nuclear medicine’s future and is a staunch advocate for patients.
Clinical Professor, Radiology - Rad/Nuclear Medicine
- Stronger Together-Collaboration Will Only Enhance Patient Care. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2023
Nuts and Bolts of Ra-223-Dichloride Therapy
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY
2022; 50 (3): 215-221
Radionuclide therapy with 223Ra-dichloride can be helpful for patients with osteoblastic osseous metastatic disease in the setting of castration resistant prostate cancer without visceral metastases. This article reviews the indications, proper use and handling, patient work-up prior to therapy and many of the technical considerations including discussion of coding/billing along with pitfalls that have been identified.
View details for DOI 10.2967/jnmt.122.263812
View details for Web of Science ID 000892612400006
View details for PubMedID 35882585